Aerie Pharmaceuticals, Inc. (AERI)
| Market Cap | 860.92M |
| Revenue (ttm) | 83.14M |
| Net Income (ttm) | -183.10M |
| Shares Out | 45.90M |
| EPS (ttm) | -3.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $18.39 |
| Previous Close | $15.81 |
| Change ($) | 2.58 |
| Change (%) | 16.32% |
| Day's Open | 16.23 |
| Day's Range | 15.76 - 18.87 |
| Day's Volume | 1,646,451 |
| 52-Week Range | 9.01 - 19.42 |
Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
Aerie (AERI) delivered earnings and revenue surprises of 19.75% and 4.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered in...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call Transcript
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Aerie has 2 marketed products and decent pipeline after a recent acquisition.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript
Aerie (AERI) delivered earnings and revenue surprises of -12.00% and -3.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Success in clinical trials doesn't guarantee success on the market.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q4 2019 Results - Earnings Call Transcript
Aerie (AERI) delivered earnings and revenue surprises of -28.00% and 24.17%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
About AERI
Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The com... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Oct 25, 2013 |
| CEO Vicente Anido | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol AERI |
Financial Performance
In 2020, AERI's revenue was $83.14 million, an increase of 18.96% compared to the previous year's $69.89 million. Losses were -$183.10 million, -8.26% less than in 2019.
Analyst Forecasts
According to 13 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 26.83, which is an increase of 45.89% from the latest price.